plozasiran
plozasiran: developed by 1 company · 8 clinical trials tracked.
plozasiran evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
How could plozasiran → ARWR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (2)
| Company | Phase |
|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Severe Hypertriglyceridemia; Hypertriglyceridemia; Familial … | Phase 3 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Familial Chylomicronemia Syndrome (FCS) | Approved |
Clinical Trials (8)
A Treatment Protocol for the Use of Plozasiran in Adults With Familial Chylomicronemia Syndrome (FCS). A Single Patient Protocol for the Use of Plozasiran In Adolescents With Familial Chylomicronemia Syndrome (FCS). An Expanded Access Treatment Protocol for Use of Plozasiran In Adults With High-Risk Severe Hypertriglyceridemia (SHTG).
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)
Primary endpoint: Time to First Occurrence of Positively Adjudicated AP Event (Event Occurring More Than 10 Days After First Dose of Study Drug)
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)
Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia
Primary endpoint: Percent change in fasting serum TG levels from baseline to Month 12 compared to placebo
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia
Primary endpoint: Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia
Primary endpoint: Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 / VSA001 / SAR449124 Injection in Chinese Adults With Familial Chylomicronemia Syndrome
Primary endpoint: Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
Primary endpoint: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG)
Frequently asked questions
Who is developing plozasiran?
plozasiran is being developed by ARROWHEAD PHARMACEUTICALS, INC..
How many clinical trials involve plozasiran?
BioSniper tracks 8 clinical trials involving plozasiran.